Navigation Links
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:6/26/2009

, ankles, feet, lower back and neck are commonly affected. Psoriasis affects an estimated two to three percent of the world's population, and approximately one out of three patients affected by psoriasis may develop psoriatic arthritis. Both men and women are equally affected by psoriatic arthritis, most commonly between the ages of 30 and 50, in the peak of their productive years.

About Ankylosing Spondylitis

Ankylosing spondylitis is a painful and progressive form of spinal arthritis, and symptoms of inflammatory back pain often first present in people under the age of 35 years. On the European continent, it is estimated that prevalence ranges from 0.2 to one percent of the entire population. It typically begins in the late teens and early 20s, and in severe cases can result in fusing of the spinal vertebrae and cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision.

About SIMPONI

SIMPONI is a human monoclonal antibody that targets and neutralizes excess TNF alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation and damage to bones, cartilage and tissue. Upon approval in the European Union, SIMPONI will be the first once-monthly subcutaneous anti-TNF-alpha therapy for the treatment of moderate-to-severe, active RA, active and progressive PsA and severe, active AS, and will be available either through the SIMPONI SmartJect(TM) auto injector or a prefilled syringe. The approved dose for SIMPONI in the US and Canada is a 50 mg subcutaneous injection given once a month.

Important Safety Information

In Europe, SIMPONI is contraindicated in patients with active tuberculosis, severe infections such as sepsis, oppo
'/>"/>

SOURCE Schering-Plough Corporation; Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
2. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
3. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
4. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
5. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
6. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
7. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
8. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
9. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
10. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
11. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 17 Cell Therapeutics, Inc. ... that on February 10, 2010 the U.S. ... Committee (ODAC) will review the New Drug ... of relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC ... evaluates data concerning the efficacy and safety ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 Today, a group of ... opposition to H.R. 3590, the Patient Protection and Affordable ... and making its way towards a final vote in ... states, urging Senators to vote against a health care ... "Physicians know first hand that our health care system ...
(Date:12/16/2009)... Tenn. , Dec. 16 MedSolutions ... cost management services, today commended two new studies ... CT scans and other diagnostic imaging tests. ... to proper diagnosis and treatment," said Gregg Allen, ... new studies offer more compelling evidence that stricter ...
Breaking Medicine Technology:Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4Physician Groups Oppose Current Senate Health Care Reform Bill 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3Businesses Need Swine Flu Action Plan U S Says 54933 1Businesses Need Swine Flu Action Plan U S Says 54933 2Businesses Need Swine Flu Action Plan U S Says 54933 3President Obama Misleads on Abortion Funding in Health Care Reform 54931 1President Obama Misleads on Abortion Funding in Health Care Reform 54931 2Novel polymer could improve protein based drugs 9631 1Novel polymer could improve protein based drugs 9631 2Novel polymer could improve protein based drugs 9631 3
... SYDNEY, Australia, Feb. 26 Fenofibrate ... by total cardiovascular events: the,composite of ... coronary,and carotid revascularization) in patients with ... is, the combination of high triglyceride ...
... LITTLETON, Mass., Feb. 26 Still River Systems announced ... high energy cyclotron magnet. Still River,s magnet is the ... of the particle accelerator that will deliver proton therapy ... installation at Barnes Jewish Hospital in St. Louis, Missouri ...
Other Medicine Technology:Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 2Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 3Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 5Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 6Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year 2
(Date:12/16/2009)... 16 New Enterprise Associates, Inc. (NEA), ... that one of its portfolio companies, Acclarent, Inc., ... acquired by Ethicon, Inc., a Johnson & Johnson ... million (net of estimated cash on hand at ... to designing, developing and commercializing devices that address ...
(Date:12/16/2009)... Immucor, Inc. (Nasdaq: BLUD ), a ... blood transfusion industry, today announced that Paul D. Mintz, ... new independent director, effective January 1, 2010. ,, ... transfusion medicine for more than 30 years. He is ... University of Virginia School of Medicine. He also serves ...
(Date:12/16/2009)... For wounded U.S. servicemen and women recovering at Walter ... can be a particularly difficult time. Wounded soldiers ... ever on the healing power of connecting with family ... easier for Walter Reed patients as Verizon Wireless donated ... of minutes of holiday talk time for 2,500 recovering ...
(Date:12/16/2009)... 16 HealthSciences Institute will sponsor ... professionals, teams and organizations who serve individuals ... diseases in employer, health plan, medical home ... will offer free, noncommercial webinars on topics, ... prevention, management and care improvement. Each webinar ...
(Date:12/16/2009)... suggests it plays a role in reducing inflammation in ... A gene variant that plays a role in inflammation ... as well as adults who smoke. , Researchers also ... MMP12 gene had a lower risk of developing chronic ... on by smoking. , "The gene seems to be ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Immucor Appoints New Board Director 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3
... , ... Washington, DC (PRWEB) December 8, 2008 -- SingaporeMedicine ... Borders: Singapore Second Edition. Following the success of the flagship ... Singapore Second Edition will be introduced at the Health Care Globalization ...
... reassurance their stress-related symptoms are treatable. , ... Dallas, ... of over 300 CEOs and businesspeople at the Warwick Melrose Hotel ... physician, Dr. Mark Anderson said with a smile, "you,re all going ...
... as ineffective in patients with chronic lymphocytic leukemia (CLL) ... II clinical trials, according to researchers at The Ohio ... and Solove Research Institute. , Together, the trials involved ... the drug flavopiridol (alvocidib). Responses were seen in approximately ...
... he was Army Chief of Staff and am proud to ... has dedicated his life to serving this nation.,He knows service ... , "The more than ... and, with record funding over the past eight years, they,deliver ...
... SAN FRANCISCO, Dec. 7 Results of the ... patients with relapsed or,refractory B-Cell non-Hodgkin,s lymphoma (NHL) ... the 50th Annual American Society of Hematology (ASH),Meeting. ... oral Syk,inhibitor is well-tolerated by these patients and ...
... FRANCISCO, December 7, 2008) Two studies examining the effects ... transplantation outcomes will be explored at a press conference taking ... 50th Annual Meeting of the American Society of Hematology in ... specialized technique for increasing the presence of stem cells in ...
Other Medicine News:Health News:Healthy Travel Media Launches Second Edition of Patients Beyond Borders Singapore Edition 2Health News:Healthy Travel Media Launches Second Edition of Patients Beyond Borders Singapore Edition 3Health News:Top Executives Tap Top Docs for Recession-Proof Relief 2Health News:Dismissed leukemia drug helps cll patients, studies show 2Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 2Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 3Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 4Health News:Research on the effects of stem cell source and patient age on transplantation outcomes 2Health News:Research on the effects of stem cell source and patient age on transplantation outcomes 3Health News:Research on the effects of stem cell source and patient age on transplantation outcomes 4Health News:Research on the effects of stem cell source and patient age on transplantation outcomes 5Health News:Research on the effects of stem cell source and patient age on transplantation outcomes 6
Non-sterile oncoseed seeds consists of a welded titanium capsule containing....
... Four 62 mirrors ... the angle with little ... flange is convenient for ... fissures. Anterior holding ring ...
Direct gonioscopy lens with magnification. The lens rests on the scleral flange creating a corneal vault and leaving the anterior chamber angle undisturbed. Three sizes available....
Shahinian lachrymal cannula, blunt tapered with side port....
Medicine Products: